At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled / 40 target
Drug / intervention
dacomitinib hydratedrug
Likely dose
dacomitinib hydrate 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Special Investigation for Vizimpro Tablets
In Brief
An observational study evaluating dacomitinib hydrate for EGFR Mutation-positive Inoperable or Reccrent NSCLC. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJan 2020
Primary CompletionApr 2025
TodayJul 2026
First PostedNov 7, 2019
Enrollment StartJan 24, 2020
Primary CompletionApr 25, 2025
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 6.7 years ago
Arms & Interventions
VIZIMPRO(dacomitinib hydrate)other
Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
Drug: dacomitinib hydrate
Interventions
dacomitinib hydratedrug
The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.